Loading
Abbott Laboratories Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Jun 2026.
Abbott Laboratories: what insiders have been doing
Abbott Laboratories, founded in 1888, is a Healthcare & Pharma company based in North Chicago, United States. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 63 filings signed by 26 insiders.
The record shows 5 purchases on the open market worth €3.3M, made by 4 insiders, against 11 sales worth €40.7M by 7 insiders. Taken together, the sales exceed the purchases by €37.5M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants. The largest single trade was a sale of €21.6M by Ford Robert B, published on 27 August 2026, equal to 0.014% of the market capitalisation.
Compared with its exchange (5,811 companies, median 19 filings), a count of 63 filings is above the norm. Since 2016, the database holds 5 purchases and 40 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 44.33 bn USD of revenue and 6.52 bn USD of net income and a dividend of 2.40 USD per share.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 18 June 2026, which is 122 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
327
Thresholds
n/a
Buy Volume
€3M
5 ops. · all time
Sell Volume
€73M
40 ops. · all time
Who traded when
BuySaleLouis H. Morrone4 sales
JOHN A. MCCOY Jr.3 sales
Robert B. Ford1 buy2 sales
Shroff Eric3 sales
Daniel J. Starks2 buys
Mary K. Moreland2 sales
+6 other insiders
Since the insiders bought
- +19.3%Entry US$87.83 · Close 15 Oct 2026 US$104.74
- +14.7%Entry US$91.33 · Close 15 Oct 2026 US$104.74
- +11.6%Entry US$93.86 · Close 15 Oct 2026 US$104.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Abbott Laboratories Strong Buy (bullish), based on 26 analysts. Average price target: US$120.72.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,815 of 24,148 companies
60.3
score / 100
Value49
Quality71
FCF yld4.1%
Earn yld3.6%
EV/EBITDA16.2x
ROE11%
Gross mgn56%
Net mgn15%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$104.68
Analyst consensus
26 analystsStrong buy
US$103.00Target US$120.72(+15%)US$135.00
Income statement
RevenueUS$44.3B
Gross profitUS$25B56% margin
EBITDAUS$12.1B27% margin
Net incomeUS$6.5B11.6% margin
Valuation
PER (trailing)33.8x
PER (forward)17.3x
P/Book3.5x
Beta0.58
Balance sheet & cash
Market capUS$182.3B
Total debtUS$13.9B
Free Cash FlowUS$7.4B
Debt / Equity63%
Profitability & ownership
ROE10.6%
ROA5.3%
% insiders0.5%
% institutions81.8%
Last declaration on 25 September 2026
Declarations327 total
52,507 shares@ US$103.990.0031% mcap100.0% of flowCommon shares without par valueSEC:0001306119-26-000009:0
52 shares@ US$110.360.0000% mcap1.0% of flowCommon shares without par valueSEC:0001644207-26-000012:0
27 shares@ US$109.540.0000% mcap0.5% of flowCommon shares without par valueSEC:0001644207-26-000012:1
388 shares@ US$110.360.0000% mcap0.7% of flowCommon shares without par valueSEC:0001805099-26-000008:0
27 shares@ US$109.51850.0000% mcap100.0% of flowCommonSEC144:0001644207-26-000010
151,869 shares@ US$44.400.0037% mcap6.2% of flowCommon shares without par valueSEC:0001612571-26-000011:0
246,963 shares@ US$59.940.0082% mcap13.5% of flowCommon shares without par valueSEC:0001612571-26-000011:1
218,535 shares@ US$115.570.014% mcap23.0% of flowCommon shares without par valueSEC:0001612571-26-000011:2
180,297 shares@ US$116.190.012% mcap19.1% of flowCommon shares without par valueSEC:0001612571-26-000011:3
398,832 shares@ US$115.84920.026% mcap100.0% of flowCommonSEC144:0001612571-26-000008
12 shares@ US$107.990.0000% mcap0.0% of flowCommon shares without par valueSEC:0001867666-26-000013:1
5,850 shares@ US$109.830.0004% mcap14.0% of flowCommon shares without par valueSEC:0001867666-26-000013:0
5,850 shares@ US$109.83010.0004% mcap100.0% of flowCommonSEC144:0001867666-26-000011
269 sharesCommon shares without par valueSEC:0001867666-26-000009:0
560 sharesCommon shares without par valueSEC:0002075371-26-000009:0
2,000 shares@ US$86.820.0001% mcap100.0% of flowCommon shares without par valueSEC:0001385262-26-000017:0
Canonical exit: 5 Aug 2026 (T+90)
5,314 shares@ US$94.410.0003% mcap11.6% of flowCommon shares without par valueSEC:0001783147-26-000009:0
2,286 shares0Common shares without par valueSEC:0000902132-26-000005:0
2,286 shares0Common shares without par valueSEC:0001294731-26-000004:0
2,286 shares0Common shares without par valueSEC:0001306119-26-000004:0
2,286 shares0Common shares without par valueSEC:0001385262-26-000012:0
2,286 shares0Common shares without par valueSEC:0001527742-26-000012:0
2,286 shares0Common shares without par valueSEC:0001537286-26-000002:0
2,286 shares0Common shares without par valueSEC:0001577544-26-000006:0
2,286 shares0Common shares without par valueSEC:0001640036-26-000004:0
25 of 327 declarations
About Abbott Laboratories
Abbott Laboratories (ticker: ABT) is a global healthcare company listed in the United States on the NYSE/NASDAQ and headquartered in Abbott Park, Illinois, United States. Founded in 1888 by Dr. Wallace C. Abbott, the company has evolved from a traditional pharmaceutical business into a diversified healthcare platform with meaningful positions across medical technologies, diagnostics, nutrition and branded generic medicines. For international investors, Abbott is typically viewed as a high-quality large-cap healthcare name with defensive characteristics, recurring revenue streams and a long record of product innovation.
Abbott’s business is organized around four main segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals. Medical Devices is now the key growth engine and includes leading franchises in diabetes care, cardiovascular therapies and other intervention-focused technologies. The company’s flagship FreeStyle Libre continuous glucose monitoring system is one of the best-known products in the sector and has helped Abbott build a strong position in diabetes technology. Abbott also sells a broad set of cardiovascular and electrophysiology products, including solutions for structural heart care, rhythm management and minimally invasive procedures. Diagnostics provides laboratory and molecular testing systems, Nutrition covers adult, pediatric and specialty nutrition, and Established Pharmaceuticals sells branded generic medicines in a broad range of international markets.
Read moreShow less
From a competitive standpoint, Abbott holds a strong position in several attractive healthcare niches thanks to its scale, regulatory expertise, global distribution and steady innovation pipeline. Its portfolio benefits from a combination of recurring consumable revenue, installed-base economics and relatively high barriers to entry in areas such as glucose monitoring and advanced cardiovascular devices. This makes Abbott particularly resilient compared with more cyclical industrial or consumer businesses, while still offering above-average growth potential for a mature healthcare company.
Geographically, Abbott has a broad global footprint, with meaningful sales in the United States and across international markets. That diversification supports earnings stability, although it also exposes the company to foreign exchange movements and different reimbursement and regulatory regimes. Recent company disclosures point to solid operational momentum: Abbott reported strong 2025 results, with growth led by Medical Devices and its base business, and it issued 2026 guidance reflecting continued expansion. In 2026, Abbott also announced the acquisition of Exact Sciences, which materially strengthens its diagnostics platform and expands its exposure to cancer screening and early detection. Overall, Abbott remains one of the most established healthcare franchises on the market, combining scale, innovation and long-term earnings quality.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
